Skip to content

Effect of dexmedetomidine combined with esketamine on postoperative fatigue in patients undergoing laparoscopic total hysterectomy

Effect of dexmedetomidine combined with esketamine on postoperative fatigue in patients undergoing laparoscopic total hysterectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094406
Enrollment
Unknown
Registered
2024-12-23
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Fatigue

Interventions

Dexmedetomidine group:Before induction, 0.5µg/kg dexmedetomidine was administered for 10min to complete pumping, and the intraoperative rate was 0.4µg/kg/h
Dexmedetomidine combined with esketamine group:Before induction, 0.5µg/kg dexmedetomidine was administered for 10 minutes to complete pumping, and after induction, 0.25mg/kg esketamine was administere

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective laparoscopic total hysterectomy; 2. ASA grade I - II; 3. Aged 18 to 65 years old; 4. BMI 18-30kg/m^2;

Exclusion criteria

Exclusion criteria: 1.The uterine lesion was malignant; 2.Patients with preoperative fatigue; 3.Allergy and contraindications to dexmedetomidine; (Patients with liver and kidney dysfunction; Patients with hypovolemia; Patients with severe heart block; Patients with severe ventricular insufficiency) 4.Allergy and contraindication to esketamine; (Patients with severe elevation of intracranial pressure; People with untreated or poorly controlled high blood pressure; Patients with glaucoma; Patients with untreated or undertreated hyperthyroidism) 5.Complicated with severe cardiovascular disease (such as myocardial infarction, heart failure, malignant arrhythmia, degree atrioventricular block, etc.), kidney disease (glomerular filtration rate =2mg/dl); 6.Recent use of antidepressants or other antidepressant treatment; 7.History of substance abuse, mental illness, communication disorders, etc.

Design outcomes

Primary

MeasureTime frame
Identity consequence fatigue scale;Christensen fatigue score;

Secondary

MeasureTime frame
Time from the end of the operation to extubation;Perioperative propofol, remifentanil consumption;Intraoperative vasoactive drug use;Incidence of postoperative nausea and vomiting;Remedial analgesics after surgery;VAS pain score;Pittsburgh Sleep Quality Index;The first time of the postoperative exhaust;Perioperative adverse reactions;

Countries

China

Contacts

Public ContactGuanglei Wang

Affiliated Hospital of Xuzhou Medical University

13852087156@163.com+86 138 5208 7156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026